Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04786730

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Attention-deficit Hyperactivity Disorder Clinical Trial

Official title:
A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-deficit Hyperactivity Disorder

Clinical Trial Summary

This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-deficit Hyperactivity Disorder
  • Hyperkinesis
Clinical Trial Details
NCT number NCT04786730
Study type Interventional
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact
Status Completed
Phase Phase 1
Start date March 9, 2021
Completion date April 26, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02827188 - Cognitive Restructuring in ADHD: Functional Training N/A
Recruiting NCT05374187 - Efficacy of Trigeminal Nerve Stimulation for ADHD N/A
Enrolling by invitation NCT04229251 - Online Mindfulness-Based Intervention for ADHD N/A
Completed NCT00339729 - Johnston County ADHD Study: Environmental, Reporductive, and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT04416360 - Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak N/A
Recruiting NCT01657721 - Working Memory Training in ADHD (The Engage Study) Phase 1
Completed NCT01323192 - An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder Phase 3
Recruiting NCT05165511 - Families, Responsibility, Education, Support, and Health for Executive Function N/A
Completed NCT01886469 - A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) Phase 1/Phase 2
Completed NCT01010750 - Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Phase 1
Recruiting NCT04729439 - Technology-Enhanced Executive Functioning Intervention for ADHD Phase 1
Completed NCT01624649 - A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors Phase 4
Completed NCT03806946 - Impact of Relationship of Epilepsy and Attention Deficit Hyperactive Disorder
Recruiting NCT05869253 - The Efficacy of Equine Assisted Occupational Therapy, for Children With Attention Deficit Hyperactivity Disorder (ADHD) on Cognitive-emotional Aspects, Daily Function and Participation N/A
Completed NCT01907360 - Pharmacokinetics of HLD200 in Children and Adolescents With ADHD Phase 1/Phase 2